Leukotrienes play a major role in the underlying pathophysiology of asthma. Leukotriene-receptor antagonists and direct leukotriene-synthesis inhibitors may be important new agents in maintenance therapy for asthma. Their role may also extend to attenuating exercise-induced and allergen-induced bronchospasm. This article reviews the effectiveness of available leukotriene modifiers in various clinical studies, reviews their adverse effects profile, and discusses their potential roles in the management of asthma.
|Original language||English (US)|
|Journal||The Journal of the American Osteopathic Association|
|Issue number||7 Suppl|
|Publication status||Published - Jul 1999|
All Science Journal Classification (ASJC) codes